Clobutinol
From Wikipedia, the free encyclopedia
Clobutinol
|
|
Systematic (IUPAC) name | |
1-(4-chlorophenyl)-4-dimethylamino-2,3-dimethyl-butan-2-ol | |
Identifiers | |
CAS number | |
ATC code | R05 |
PubChem | |
Chemical data | |
Formula | C14H22ClNO |
Mol. mass | 255.783 g/mol |
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | ? |
Half life | ? |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | ? |
Clobutinol is a cough suppressant distributed by Boehringer-Ingelheim, Novartis's Hexal (Sandoz), Stada and possibly other companies.
[edit] Side effects and withdrawal
It was recently determined to cause cardiac arrhythmia in some patients.
Recent studies have indicated that clobutinol has the potential to prolong the QT interval.[1][2].
Boehringer Ingelheim products containing clobutinol were withdrawn from sale in Germany, and the rest of the world, on August 31, 2007[3] [4][5].
[edit] See also
[edit] References
- ^ Bellocq C, Wilders R, Schott JJ, et al (2004). "A common antitussive drug, clobutinol, precipitates the long QT syndrome 2". Mol. Pharmacol. 66 (5): 1093–102. doi: . PMID 15280442.
- ^ Expert statement on BfArM website: [1]. Retrieved 2007-SEP-01.
- ^ Yahoo! News: Bundesinstitut ruft Hustenmittel zurück [in German]. Retrieved 2007-AUG-31.
- ^ tagesschau.de: Bundesinstitut verbietet Hustenmittel Clobutinol [in German]. Retrieved 2007-AUG-31.
- ^ Company Website:Boehringer Ingelheim voluntarily withdraws its clobutinol containing medications [English]. Retrieved 2007-Sep-01.
|